Supporting the Aspecific Physiological Defenses of Upper Airways against Emerging SARS-CoV-2 Variants

doi:10.3390/pathogens12020211

Editorial

. 2023 Jan 29;12(2):211.

doi: 10.3390/pathogens12020211.

Supporting the Aspecific Physiological Defenses of Upper Airways against Emerging SARS-CoV-2 Variants

Luca Cegolon^{1

2}, Giuseppe Mastrangelo³, Saverio Bellizzi⁴, Francesca Larese Filon^{1

2}, Cristiano Salata⁵

Affiliations

¹ Department of Medical, Surgical & Health Sciences, University of Trieste, 34129 Trieste, Italy.
² Occupational Medicine Unit, University Health Agency Giuliano-Isontina (ASUGI), 34129 Trieste, Italy.
³ Senior Researcher, University of Padua, 35121 Padua, Italy.
⁴ Independent Researcher, 1202 Geneva, Switzerland.
⁵ Department of Molecular Medicine, University of Padua, 35121 Padua, Italy.

PMID: 36839483
PMCID: PMC9964793
DOI: 10.3390/pathogens12020211

Editorial

Supporting the Aspecific Physiological Defenses of Upper Airways against Emerging SARS-CoV-2 Variants

Luca Cegolon et al. Pathogens. 2023.

. 2023 Jan 29;12(2):211.

doi: 10.3390/pathogens12020211.

Authors

Luca Cegolon^{1

2}, Giuseppe Mastrangelo³, Saverio Bellizzi⁴, Francesca Larese Filon^{1

2}, Cristiano Salata⁵

Affiliations

¹ Department of Medical, Surgical & Health Sciences, University of Trieste, 34129 Trieste, Italy.
² Occupational Medicine Unit, University Health Agency Giuliano-Isontina (ASUGI), 34129 Trieste, Italy.
³ Senior Researcher, University of Padua, 35121 Padua, Italy.
⁴ Independent Researcher, 1202 Geneva, Switzerland.
⁵ Department of Molecular Medicine, University of Padua, 35121 Padua, Italy.

PMID: 36839483
PMCID: PMC9964793
DOI: 10.3390/pathogens12020211

Abstract

The rapid rollout of COVID-19 vaccines in 2021 sparked general optimism toward controlling the severe form of the disease, preventing hospitalizations and COVID-19-associated mortality, and the transmissibility of SARS-CoV-2 infection [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Cited by

Significance of saline nasalirrigation for COVID-19 infection: observations and reflections from nursing care of nasopharyngeal carcinoma.
Yan L, Ding J, Xu M, Lin X, Mejia MBA, Chen J, Xu Y, Hong H, Chen L. Yan L, et al. Transl Cancer Res. 2024 Feb 29;13(2):1114-1124. doi: 10.21037/tcr-23-2384. Epub 2024 Feb 28. Transl Cancer Res. 2024. PMID: 38482412 Free PMC article.
Activity of N-Chlorotaurine against Periodontal Pathogens.
Kowalczyk K, Coraça-Huber DC, Wille-Kollmar W, Berktold M, Nagl M. Kowalczyk K, et al. Int J Mol Sci. 2024 Jul 30;25(15):8357. doi: 10.3390/ijms25158357. Int J Mol Sci. 2024. PMID: 39125925 Free PMC article.
COVID-19 Incidence and Vaccine Effectiveness in University Staff, 1 March 2020-2 April 2022.
Cegolon L, Negro C, Pesce M, Filon FL. Cegolon L, et al. Vaccines (Basel). 2023 Feb 19;11(2):483. doi: 10.3390/vaccines11020483. Vaccines (Basel). 2023. PMID: 36851360 Free PMC article.
SARS-COV-2 breakthrough infection and its covariates among healthcare providers of a hospital in Bangladesh during the omicron wave.
Akhter M, Roy SK, Khair A, Karim MR, Mojlish UKFK, Ahmed MU, Ali L. Akhter M, et al. Heliyon. 2024 Sep 2;10(17):e37287. doi: 10.1016/j.heliyon.2024.e37287. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39296236 Free PMC article.
Dominant CT Patterns and Immune Responses during the Early Infection Phases of Different SARS-CoV-2 Variants.
Nagaoka K, Kawasuji H, Takegoshi Y, Murai Y, Kaneda M, Kimoto K, Tani H, Niimi H, Morinaga Y, Noguchi K, Yamamoto Y. Nagaoka K, et al. Viruses. 2023 May 31;15(6):1304. doi: 10.3390/v15061304. Viruses. 2023. PMID: 37376606 Free PMC article.

See all "Cited by" articles

References

1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael A., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
1. Voysey M., Costa Clemens S.A., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet. 2021;397:881–891. doi: 10.1016/S0140-6736(21)00432-3. - DOI - PMC - PubMed
1. Pires L., Wilson B.C., Bremner R., Lang A., Larouche J., McDonald R., Pearson J.D., Trcka D., Wrana J., Wu J., et al. Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2. Sci. Rep. 2022;12:14438. doi: 10.1038/s41598-022-18513-0. - DOI - PMC - PubMed
1. Cegolon L., Negro C., Mastrangelo g Larese Filon F. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021–31 May 2022. Viruses. 2022;14:2688. doi: 10.3390/v14122688. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael A., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed

[2] Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael A., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed

[3] Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed

[4] Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed

[5] Voysey M., Costa Clemens S.A., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet. 2021;397:881–891. doi: 10.1016/S0140-6736(21)00432-3. - DOI - PMC - PubMed

[6] Voysey M., Costa Clemens S.A., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet. 2021;397:881–891. doi: 10.1016/S0140-6736(21)00432-3. - DOI - PMC - PubMed

[7] Pires L., Wilson B.C., Bremner R., Lang A., Larouche J., McDonald R., Pearson J.D., Trcka D., Wrana J., Wu J., et al. Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2. Sci. Rep. 2022;12:14438. doi: 10.1038/s41598-022-18513-0. - DOI - PMC - PubMed

[8] Pires L., Wilson B.C., Bremner R., Lang A., Larouche J., McDonald R., Pearson J.D., Trcka D., Wrana J., Wu J., et al. Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2. Sci. Rep. 2022;12:14438. doi: 10.1038/s41598-022-18513-0. - DOI - PMC - PubMed

[9] Cegolon L., Negro C., Mastrangelo g Larese Filon F. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021–31 May 2022. Viruses. 2022;14:2688. doi: 10.3390/v14122688. - DOI - PMC - PubMed

[10] Cegolon L., Negro C., Mastrangelo g Larese Filon F. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021–31 May 2022. Viruses. 2022;14:2688. doi: 10.3390/v14122688. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Supporting the Aspecific Physiological Defenses of Upper Airways against Emerging SARS-CoV-2 Variants

Affiliations

Supporting the Aspecific Physiological Defenses of Upper Airways against Emerging SARS-CoV-2 Variants

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources

Miscellaneous